Meeting Your Molecular Diagnostics Needs
ACT Genomics offers a broad range of genomic assays – from comprehensive to smaller targeted panels – that empower physicians with evidence-based genomic insights for disease management.
Why ACT Genomics?
High success rate of sequencing to result
Enhanced laboratory protocols to achieve high-performance sequencing to result even with a limited specimen.
Up-to-date database with clinical actionability
Periodically updated databases to ensure relevant clinical application.
On-time result delivery with support
Short TAT to meet physicians and patients' time constraints with post-service support i.e., 1-on-1 report consultation.
A trusted brand with high credibility & reliability
Internationally recognized and engaged by major cancer hospitals and clinics.
Our Tests & Their Focuses
Wide range of genomic profiling panels, tailored for different focuses and clinician needs, requiring either tissue and/or liquid biopsy.
TREATMENT SELECTION
DISEASE MONITORING
RISK PREDICTION
Compare Our Tests
Find the most suitable test for you
What the test does
Provides comprehensive genetic information on potential therapeutic response (i.e. to targeted therapy, chemotherapy, immunotherapy)
Incorporates pathway-based analysis for a holistic overview & therapeutic recommendations
Focuses on clinically recommended biomarkers for targeted therapies
Focuses on biomarkers associated with lung cancer for targeted therapy
Identifies clinically relevant and future potential fusion biomarkers
Provides comprehensive genetic information for Somatic and/or Germline BRCA1/2 mutations (2 panels available: tissue or blood based)
Determines BRCA 1/2, LOH and HRD status for PARP inhibitor treatment
Monitors disease burden and treatment response/resistance
Monitors disease burden and treatment response/resistance
Monitors disease burden and treatment response/resistance
Monitors disease burden and treatment response/resistance
Provides targetable drug options using cerebrospinal fluid (CSF)
Evaluates and manages hereditary cancer risk#
Cancer types covered
All types of solid tumors (including common & rare cancers)
Common cancer types: lung cancer, gastric cancer, colon cancer, prostate cancer, etc.
Lung cancer
All types of solid tumors
BRCA-associated cancers: ovarian cancer, breast cancer, pancreatic cancer, prostate cancer
Ovarian cancer and HRD-/HRR-related cancer types†
Other solid tumors (Pan-cancer)
Lung cancer
Breast cancer
Colon cancer
Brain metastases from lung cancer, breast cancer, etc.
9 major hereditary cancers & 11 hereditary cancer syndromes
Genes covered
440 cancer-related genes (including 13 fusion genes)
40 actionable genes (including 13 fusion genes)
13 lung-cancer-related genes (including 8 fusion genes)
13 fusion genes (covering both known & novel fusion transcripts)
BRCA1 & BRCA2
24 HRR-related genes (including BRCA1/2)
50 cancer-related genes
11 Lung-cancer-related genes
8 Breast-cancer-related genes
13 Colon-cancer-related genes
40 actionable genes
67 hereditary-cancer-related genes
Type of patients
All major solid tumors
Newly diagnosed, advanced, recurrent and metastatic cancer
Common solid tumors with biomarker focus
Newly diagnosed, advanced, recurrent and metastatic cancer
Non small cell lung cancer (NSCLC)
Newly diagnosed and metastatic cancer
All major solid tumors
Newly diagnosed, advanced, recurrent and metastatic cancer
Considering PARP inhibitor treatment
Newly diagnosed, advanced, recurrent and metastatic cancer
Considering PARP inhibitor treatment
Newly diagnosed, advanced, recurrent and metastatic cancer
Other solid tumors (Pan-cancer)
Newly diagnosed, advanced, recurrent and metastatic cancer
Lung cancer
Newly diagnosed, advanced, recurrent and metastatic cancer
Breast cancer
Newly diagnosed, advanced, recurrent and metastatic cancer
Colon cancer
Newly diagnosed, advanced, recurrent and metastatic cancer
All major solid tumors with brain metastases
Advanced, recurrent and metastatic cancer
An individual with a family history of cancer
An individual with multiple cancers
An individual with an early-onset or a rare cancer
An individual who is concerned about their risk of getting hereditary cancer
Couples who intend to start a family and want to know if they carry a cancer-causing genetic mutation§
Turnaround time ( *starting from the date of receipt of approved samples at our CAP-accredited laboratory)
10 working days*
8 working days*
8 working days*
10 working days*
10 working days*
10 working days*
10 working days*
10 working days*
10 working days*
10 working days*
8 working days*
12 working days*
Specimen requirements *refer to our specimen instructions
Tumor tissue (FFPE)
Tumor tissue (FFPE)
Tumor Tissue (FFPE)
Tumor tissue (FFPE)
Tumor tissue (FFPE) or Blood
Tumor tissue (FFPE)
Blood
Blood
Blood
Blood
Cerebrospinal fluid (CSF)
Blood
†Mutational profiling of HRR genes can be applied to other cancer types such as breast, pancreatic or prostate cancers.
# Genetic counselling is highly recommended prior to taking a genetic test for hereditary cancer screening.
§ For family planning, both members of the couple need to be tested so that the genetic counsellor can provide a complete review and recommendations.
Doctors View : Treatment with Better Precision through Cancer Genetic Profiling
In the era of precision medicine, what are the advanced diagnostic tools available for cancer management? We ask oncologists to share their views and experiences.
Clinical News
Publications
How to Order
Step 1
Contact Us
Contact your local ACTG representative or email us at service.sg@actgenomics.com to order a test.
Step 2
Prepare Specimen & Forms
Prepare tumor (FFPE) and/or blood specimen, as well as the associated documentation.
Step 3
Courier of Specimen Kit
Contact an ACTG representative for assistance with logistics and shipping documentation.
Step 4
Results Report Sent
An electronic version of the results report will be emailed to you. A 1-on-1 report consultancy will be provided upon request.
If you have any questions on how to order our tests, please feel free to contact us.
FAQs
-
How do I decide which ACT Genomics panel is the most suitable for my patients?
Our ACTG staff will be able to advise you on the most appropriate panel based on the information you provide, such as cancer type, objectives of the test, biomarker/s of interest, financial considerations, etc.
-
How do I interpret the ACT Genomics report?
ACT Genomics provides a 1-on-1 consultation with one of our experts to extract all the useful information that can be found from the report. In addition, our Medical Science Liaison (MSL)team is able to further assist you in finding appropriate clinical evidence based on the results in the report.
-
Why should I consider ACT Genomics instead of other providers to do the genomic testing?
Our laboratory meets the strictest laboratory standards set out by the College of American Pathology (CAP). In addition to our CAP accreditation, ACT Genomics provides a variety of high-quality genomic tests that are focused on different requirements. This variety will provide you with the option to pick the most appropriate and cost-effective test for your patient's needs. In addition, in the rare case that your patient's sample does not meet the chosen panel requirements, you will be able to choose a more suitable panel from our extensive range. This will avoid having to waste your patient's sample and you having to search out other options (i.e., other genomic testing providers etc.).
-
Is ACT Genomics test recognized by insurance companies?
The cost of our tests have been successfully claimed by patients. The success of reimbursement by an insurance company is also determined on several other factors namely i) insurance type and coverage chosen by the patients; ii) the reason for performing genomic testing, etc. We would recommend you encourage your patient to contact their healthcare insurance provider.
-
What kind of sample can be used for genomic testing?
ACT Genomics is able to perform testing on the following samples: Tissue (FFPE), Blood, DNA, Cell block (≥1x106), and Cerebrospinal fluid (CSF). Tissue (FFPE) blocks and slides are the most commonly received samples and are often the preferred sample of genomic testing providers.